

# Criteria-Based Consultation Prescribing Program

## CRITERIA FOR DRUG COVERAGE

### Tazemetostat (Tazverik)

**Notes:**

- Quantity limits: Yes

**Initiation (new start) criteria:** Non-formulary **tazemetostat (Tazverik)** will be covered on the prescription drug benefit when the following criteria are met:

- Prescribed by a hematologist or oncologist
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0-2
- Patient has one of the following diagnoses:
  1. Diagnosis of epithelioid sarcoma, metastatic or locally advanced
    - Patient is not eligible for complete resection - **AND-**
    - Patient has an integrase interactor 1 (INI1)-deficient tumor
  - OR-
  2. Diagnosis of follicular lymphoma, relapsed/refractory
    - Patient has received treatment with at least two prior chemotherapy regimens, including an anti-CD20 targeted agent -**AND-**
    - Patient has an EZH2 mutation
  - OR-
  3. Diagnosis of follicular lymphoma, relapsed/refractory
    - Patient has no alternative treatment options -**AND-**
    - Patient with unknown mutation status or EZH2 wild type (WT)

**Criteria for current Kaiser Permanente members already taking the medication who have not been reviewed previously:** Non-formulary **tazemetostat (Tazverik)** will be covered on the prescription drug benefit when the following criteria are met:

- Patient has one of the following diagnoses:
  1. Diagnosis of epithelioid sarcoma, metastatic or locally advanced
  - OR-
  2. Diagnosis of follicular lymphoma, relapsed/refractory

# Criteria-Based Consultation Prescribing Program CRITERIA FOR DRUG COVERAGE

## Tazemetostat (Tazverik)

**Criteria for *new members entering Kaiser Permanente already taking the medication who have not been reviewed previously*:** Non-formulary **tazemetostat (Tazverik)** will be covered on the prescription drug benefit when the following criteria are met:

- Patient has one of the following diagnoses:
  1. Diagnosis of epithelioid sarcoma, metastatic or locally advanced

**-OR-**

  2. Diagnosis of follicular lymphoma, relapsed/refractory

kp.org

Revised: 06/10/21  
Effective: 08/19/21

All plans offered and underwritten by  
Kaiser Foundation Health Plan of the Northwest